Serological Markers of Clinical Improvement in MuSK Myasthenia Gravis.

Gregorio Spagni Angela Vincent Bo Sun Silvia FalsoLeslie W JacobsonSean DevenishAmelia Evoli Valentina Damato

Published in: Neurology(R) neuroimmunology & neuroinflammation (2024)

Our data support the quantification of MuSK antibodies by flow cytometry. Through a multimodal investigational approach, we showed that total MuSK-IgG levels, MuSK-IgG4 and MuSK-IgG2 levels, and MuSK-IgG affinity may represent promising biomarkers of disease outcomes in MuSK-MG.

Keyphrases

flow cytometry
myasthenia gravis
clinical trial
metabolic syndrome
mass spectrometry
pain management
chronic pain
skeletal muscle
insulin resistance
open label
glycemic control